Targeted Therapies Licensing and Partnering Summit Asia

With fast, cost-effective clinical infrastructure, generous government incentives, and simplified regulatory pathways, Asia’s biotech ecosystem has emerged as a global launchpad for innovation. Western pharma and biotech companies are increasingly turning to de-risked assets from Asia to supercharge their clinical pipelines and gain a competitive edge.

Already running in the US, the Targeted Therapies Partnering and Licensing Summit Asia is built to gather a regional, critical mass of ADC, Bispecific Antibody, T-Cell Engager, Targeted Protein Degradation, and Radiopharmaceutical platforms and pipelines, so that global multi-national (MNC) pharma can connect with biotech business development and discuss new licensing and co-development opportunities.

For NewCo, private and public biotech or small pharma, this accessible forum offers:

High seniority and quality of attendees across pharma and other biotech
Targeted focus, purpose-built format, and One-on-One Partnering™ portal allowing you to make meaningful connections easier and more efficient
Informative presentations and discussions nuanced to considerations for deal-making across targeted therapies
Global exposure, local advantage. Pharma can assess related programs back-to-back and biotech can meet multiple, international big pharma.


URLs:
Website: https://go.evvnt.com/3281841-0?pid=2874
Brochure: https://go.evvnt.com/3281841-3?pid=2874

Category: Conferences | Science, Health and Medicine

Prices:
Conference Pass - Drug Developer Pricing: USD 1749.00,
Conference Pass - Academic Pricing: USD 1549.00

Speakers: Eric Chou, Translational Medicines Associate Director, AnHorn Medicines, Jeng Her, Chief Executive Officer, AP Biosciences, Tomohiro Yamauchi, Head of Global Scouting and Transaction, Astellas Pharma, Zou Bin, Chief Executive Officer, Axcynsis, Ziping Wei, Co-founder and Chief Executive Officer, Bliss Bio, Tamon Hayashi, Oncology Lead, Executive Director, Business Development, Eisai, Stefan Hart, Vice President - Oncology External Innovation, Johnson and Johnson, Helen Chen, Greater China Managing Partner, L.E.K. Consulting, Koji Yashiro, Director, Pacific Business Development and Licensing, MSD, Xiaodong Zhang, Director of Search and Evaluation, Oncology and Haematology, Novartis AG, Jeff Cleland, Co-Founder, Nurix Therapeutics, Heidi Wang, Chief Executive Officer, OBI Pharma, Marija Tadin-Strapps, Discovery Network, Discovery Early Development, Pfizer Research and Development Head, Pfizer, Brent Meadows, Chief Business Officer, Polymed Biopharmaceuticals, Daeseung Lee, Chief Executive Officer, Portrai, Jon Bernardini, Co-Founder and Chief Executive Officer, Proxima Bio, Riccardo Canevari, Chief Executive Officer, RadioPharm Theranostics, Yoshitsugu Shitaka, President and Chief Executive Officer, RealizeEdge Partners, Takumi Matsumoto, Business Development Senior Manager, Roche, Dan Zheng, Head of Regional Innovation and Partnerships, Takeda